Received Jun 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | — | IM / LL |
Adverse Event(s): On May 20, 2025, while I was present with my child, a potential vaccine administration error occurred. I was informed by staff member that the vaccine being administered was Vaxelis, despite previous documentation from an April 29 visit indicating my child was due for the Hepatitis A (Hep A) vaccine. I voiced this concern directly before administration, but provider proceeded with the vaccination regardless. Treatment: A vaccine was administered?initial documentation identified it as Vaxelis. This was later revised to show that Hep A had been given, but the patient portal still lists Vaxelis. No immediate physical symptoms or adverse reactions were observed following the vaccination. Outcome(s): The conflicting verbal and written information created significant confusion and concern about the accuracy of medical records and the vaccine received. While no physical symptoms have been reported to date, the documentation conflict and lack of confirmation procedures present a serious risk to patient safety and future care decisions. The issue remains unresolved in the digital health chart.
N/A
N/A
N/A
N/A
No medical tests or laboratory results were conducted in direct response to the adverse event on May 20, 2025. Since no immediate physical symptoms or complications were observed following the vaccine administration, no blood work, diagnostic imaging, or clinical tests were deemed necessary at the time. The concerns raised were primarily related to documentation discrepancies, vaccine identification, and potential protocol violations, rather than observable medical symptoms.